- The US FDA has approved GAMMAGARD LIQUID ERC [immune globulin infusion (human)] for treating primary immunodeficiency (PI) pts (age≥2); commercialization will be anticipated in 2026 and in the EU in 2027, where it’s approved as DEQSIGA by the EMA
- GAMMAGARD LIQUID ERC is a 10% ready-to-use IG therapy with ≤2 µg/mL IgA, for IV or SC use approved in the U.S. for PI pts (age≥2)
- In parallel with this approval, due to outdated manufacturing, Takeda will discontinue GAMMAGARD S/D, its first-generation low-IgA IG product, by the end of 2027. Inventory will be available until depleted or expires
Ref: Takeda | Image: Takeda | Press Release
Related News:- Takeda’s Adcetris Regimen Receives the EC’s Approval to Treat Newly Diagnosed Hodgkin Lymphoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
